Table 1: Main studies on EGFR TKIs for elderly ( 70 years) patients with advanced NSCLC.

AuthorStudy armNo. of patientsResponse rate (%)Median OS (months)

Shepherd* et al. [31]Erlotinib versus11287.6
Placebo5005.0
Wheatley-Price§ et al. [32]Erlotinib801010.9
Crinò§ et al. [29]Gefitinib versus993.15.9
Vinorelbine975.18.0

2 n d or 3rd -line; §first -line.